199 related articles for article (PubMed ID: 34791790)
1. Assembly of pH-Responsive Antibody-Drug-Inspired Conjugates.
Raabe M; Heck AJ; Führer S; Schauenburg D; Pieszka M; Wang T; Zegota MM; Nuhn L; Ng DYW; Kuan SL; Weil T
Macromol Biosci; 2022 Feb; 22(2):e2100299. PubMed ID: 34791790
[TBL] [Abstract][Full Text] [Related]
2. Cleavable linkers in antibody-drug conjugates.
Bargh JD; Isidro-Llobet A; Parker JS; Spring DR
Chem Soc Rev; 2019 Aug; 48(16):4361-4374. PubMed ID: 31294429
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
4. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
5. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
6. New Technologies Bloom Together for Bettering Cancer Drug Conjugates.
Jin Y; Edalatian Zakeri S; Bahal R; Wiemer AJ
Pharmacol Rev; 2022 Jul; 74(3):680-711. PubMed ID: 35710136
[TBL] [Abstract][Full Text] [Related]
7. Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope.
Yamaguchi A; Anami Y; Ha SYY; Roeder TJ; Xiong W; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
Bioorg Med Chem; 2021 Feb; 32():116013. PubMed ID: 33482584
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
9. Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates.
Acchione M; Kwon H; Jochheim CM; Atkins WM
MAbs; 2012; 4(3):362-72. PubMed ID: 22531451
[TBL] [Abstract][Full Text] [Related]
10. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
Frigerio M; Kyle AF
Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
[TBL] [Abstract][Full Text] [Related]
11. Peptide-Drug Conjugate: A Novel Drug Design Approach.
Ma L; Wang C; He Z; Cheng B; Zheng L; Huang K
Curr Med Chem; 2017; 24(31):3373-3396. PubMed ID: 28393694
[TBL] [Abstract][Full Text] [Related]
12. Peptide Drug Conjugates and Their Role in Cancer Therapy.
Heh E; Allen J; Ramirez F; Lovasz D; Fernandez L; Hogg T; Riva H; Holland N; Chacon J
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614268
[TBL] [Abstract][Full Text] [Related]
13. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
15. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
16. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
[TBL] [Abstract][Full Text] [Related]
17. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
[TBL] [Abstract][Full Text] [Related]
18. Toward a Ferrous Iron-Cleavable Linker for Antibody-Drug Conjugates.
Spangler B; Kline T; Hanson J; Li X; Zhou S; Wells JA; Sato AK; Renslo AR
Mol Pharm; 2018 May; 15(5):2054-2059. PubMed ID: 29569925
[TBL] [Abstract][Full Text] [Related]
19. Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs).
Yao H; Jiang F; Lu A; Zhang G
Int J Mol Sci; 2016 Feb; 17(2):. PubMed ID: 26848651
[TBL] [Abstract][Full Text] [Related]
20. Effect of attachment site on stability of cleavable antibody drug conjugates.
Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
